{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:19:22Z","timestamp":1784114362013,"version":"3.55.0"},"reference-count":21,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,18]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>In 82 patients with classic Hodgkin lymphoma, stable gonadal hormone levels were observed up to 24 months after nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) first-line treatment. These findings suggest preserved gonadal function and fertility after 4\u00d7N-AVD. The trial was registered at www.clinicaltrials.gov as NCT03004833.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031809","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:10:40Z","timestamp":1775153440000},"page":"3118-3121","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Gonadal function and fertility after Hodgkin lymphoma treatment with nivolumab-AVD in the phase 2 GHSG NIVAHL trial"],"prefix":"10.1182","volume":"147","author":[{"given":"Anne Sophie","family":"Robertz","sequence":"first","affiliation":[{"name":"1Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, and German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"B\u00fchnen","sequence":"additional","affiliation":[{"name":"1Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, and German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Meissner","sequence":"additional","affiliation":[{"name":"2Medicine V, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolin","family":"Trautmann-Grill","sequence":"additional","affiliation":[{"name":"3Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Herhaus","sequence":"additional","affiliation":[{"name":"4Clinic and Policlinic for Internal Medicine III, Klinikum Rechts der Isar, School of Medicine, Technical University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa V.","family":"Halbsguth","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Oncology, Department of Medicine II, Goethe University Hospital Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valdete","family":"Schaub","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine II, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kerkhoff","sequence":"additional","affiliation":[{"name":"7Medizinische Klinik A, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Mathas","sequence":"additional","affiliation":[{"name":"8Division of Hematology, Oncology, and Tumor Immunology, Charit\u00e9 Universit\u00e4tsmedizin Berlin and Max Delbr\u00fcck Center for Molecular Medicine, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bormann","sequence":"additional","affiliation":[{"name":"9Medical Department I, Klinikum Bremen-Mitte, Bremen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9794-9875","authenticated-orcid":false,"given":"Andreas","family":"Dickhut","sequence":"additional","affiliation":[{"name":"10Tumorklinik, Klinikum Fulda, Fulda, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9338-2624","authenticated-orcid":false,"given":"Christian P.","family":"Jaworek","sequence":"additional","affiliation":[{"name":"1Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, and German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fuchs","sequence":"additional","affiliation":[{"name":"1Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, and German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2909-0826","authenticated-orcid":false,"given":"Carsten","family":"Kobe","sequence":"additional","affiliation":[{"name":"11Department of Nuclear Medicine and German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1733-6064","authenticated-orcid":false,"given":"Christian","family":"Baues","sequence":"additional","affiliation":[{"name":"12Department of Radiation Oncology and German Hodgkin Study Group, Hospital Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[{"name":"1Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, and German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1410-4487","authenticated-orcid":false,"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[{"name":"1Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, and German Hodgkin Study Group, Cologne, Germany"},{"name":"13Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (Partner Site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7035-1784","authenticated-orcid":false,"given":"Karolin","family":"Behringer","sequence":"additional","affiliation":[{"name":"1Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, and German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9662-9900","authenticated-orcid":false,"given":"Paul J.","family":"Br\u00f6ckelmann","sequence":"additional","affiliation":[{"name":"1Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, and German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2026061811220089200_bib1","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2026061811220089200_bib2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"2026061811220089200_bib3","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized german Hodgkin Study Group phase II NIVAHL trial","volume":"41","author":"Br\u00f6ckelmann","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17_suppl","key":"2026061811220089200_bib4","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"J Clin Oncol"},{"issue":"21","key":"2026061811220089200_bib5","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"issue":"23","key":"2026061811220089200_bib6","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15","key":"2026061811220089200_bib7","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026061811220089200_bib8","article-title":"3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma [abstract]","volume":"146","author":"Herrera","year":"2025","journal-title":"Blood"},{"issue":"6","key":"2026061811220089200_bib9","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/S2352-3026(25)00051-1","article-title":"Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies","volume":"12","author":"Br\u00f6ckelmann","year":"2025","journal-title":"Lancet Haematol"},{"issue":"10","key":"2026061811220089200_bib10","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S1470-2045(18)30500-X","article-title":"Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin\u2019s lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial","volume":"19","author":"Anderson","year":"2018","journal-title":"Lancet Oncol"},{"issue":"30","key":"2026061811220089200_bib11","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.1200\/JCO.2005.08.138","article-title":"Secondary amenorrhea after Hodgkin\u2019s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin\u2019s Lymphoma Study Group","volume":"23","author":"Behringer","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026061811220089200_bib12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","article-title":"Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials","volume":"31","author":"Behringer","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026061811220089200_bib13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(25)00262-1","article-title":"Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial","volume":"26","author":"Ferdinandus","year":"2025","journal-title":"Lancet Oncol"},{"issue":"8","key":"2026061811220089200_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43018-022-00413-x","article-title":"Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice","volume":"3","author":"Winship","year":"2022","journal-title":"Nat Cancer"},{"issue":"2","key":"2026061811220089200_bib15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bjh.15566","article-title":"Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom","volume":"184","author":"Br\u00f6ckelmann","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"2026061811220089200_bib16","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/bjh.19307","article-title":"Patient preferences in the treatment of stage III\/IV classic Hodgkin lymphoma: results from the CONNECT cross-sectional survey","volume":"204","author":"Flora","year":"2024","journal-title":"Br J Haematol"},{"issue":"2","key":"2026061811220089200_bib17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/1078-0432.CCR-20-3303","article-title":"Early response to first-line anti\u2013PD-1 treatment in Hodgkin lymphoma: a PET-based analysis from the prospective, randomized phase II NIVAHL trial","volume":"27","author":"Voltin","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2026061811220089200_bib18","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S1470-2045(23)00390-X","article-title":"Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement","volume":"24","author":"Cui","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026061811220089200_bib19","doi-asserted-by":"crossref","first-page":"4602129","DOI":"10.1155\/2017\/4602129","article-title":"Male hypogonadism and osteoporosis: the effects, clinical consequences, and treatment of testosterone deficiency in bone health","volume":"2017","author":"Golds","year":"2017","journal-title":"Int J Endocrinol"},{"issue":"6","key":"2026061811220089200_bib20","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.3390\/ijms24065814","article-title":"Hormone-related and drug-induced osteoporosis: a cellular and molecular overview","volume":"24","author":"Wang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2026061811220089200_bib21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-025-01012-2","article-title":"Hodgkin lymphoma: great progress with room for improvement","volume":"22","author":"Br\u00f6ckelmann","year":"2025","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/25\/3118\/2528281\/blood_bld-2025-031809-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/25\/3118\/2528281\/blood_bld-2025-031809-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:22:12Z","timestamp":1781796132000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/25\/3118\/567561\/Gonadal-function-and-fertility-after-Hodgkin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":21,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2026,6,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031809","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,18]]},"published":{"date-parts":[[2026,6,18]]}}}